Call for Grant Notification: Genentech Medical Education & Research Grants

The Medical Education & Research Grants Team at Genentech, a member of the Roche Group, invites members of the research community to submit applications for innovative research grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific needs exist and funding is available.

Purpose: As part of our scientific mission, Genentech provides grants for scientific projects and fellowship programs that are aligned with our mission to (1) foster advances in scientific research and discovery; and (2) support advanced study by clinical and research professionals at accredited universities or training institutions. Genentech CGNs are posted on the Genentech website (http://funding.gene.com) along with the several social media outlets. In addition, an email is sent out to all registered users of the Genentech Financial Request System (gFRS) who have previously submitted an application for support of an independent education activity.

Eligibility Criteria: Applicant must be registered on the Genentech Financial Request System (gFRS).

Geographical Scope: The research activity must be U.S.-based only unless specifically identified as a Global Grant.

Submission Instructions:
1. Researchers who meet the eligibility criteria and are interested in submitting a response to this CGN submit applications online through gFRS, which can be accessed via http://funding.gene.com. When submitting the application, please be sure the following are completed:
   a. Select the Therapeutic Area, and the Disease State for the grant(s) that you are submitting.
   b. Include “CGN_RES_August 2015 [Insert Program Title]” in the program title of the grant application
   c. Complete all sections of online grant request form
   d. Upload all documentation as requested by the system
   e. Deadline for Submission of Application(s): [September 30th, 2015] (11:59 PM Pacific Time)

Award Decision Date/Mechanism: Approvals and denials will be communicated via standard grant-submission means (email notifications) no later than [October 30th, 2015]. There have been no pre-determined approvals, nor any identified preferred researchers. All submissions will be reviewed equally and thoroughly.

Researchers should not respond to this CGN unless they have read and understand the terms, purpose, therapeutic landscape, and research request identified below. Applicants will be expected to identify independent gaps that are scientifically accurate and relevantly aligned to these CGNs.

Potential applicants should carefully review the funding requirements and restrictions posted on the following webpage prior to starting their application: http://www.gene.com/good/grants/scientific-project-support

<table>
<thead>
<tr>
<th>Therapeutic Area and Disease Area</th>
<th>[Advanced Neurodegenerative Disease Research. (1 research project budget approximately $100,000)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>Neurodegenerative disease such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington’s Disease (HD) are progressive, age-related biologically complex diseases with increasing prevalence in our population and as of yet, no cure or lasting therapy. As the world population grows older, the prevalence of these diseases is increasing and estimated to double by the year 2030 at significant cost and burden to healthcare services (1). Progress into our understanding of the pathophysiology of these diseases and advancing current treatment options have been slow due in part to cryptic disease onset, insidious progression, and the lack of effective biomarkers (2-4).</td>
</tr>
</tbody>
</table>

Methods

Genentech is seeking to support 1 research project that is designed to improve our understanding of neurodegenerative diseases. The proposed research can be focused on any one of a number of basic, translational or clinical research topics that will
improve our understanding of the onset, progression or treatment of neurodegenerative diseases such as AD, PD, ALS or HD.

**Measures and Results**

The successful research project will incorporate a groundbreaking exploration of neurodegenerative disease. Potential applicants are encouraged to describe how their proposed research—if successful—may impact our understanding of and the real-world treatment of patients with neurodegenerative disease.

**Additional Considerations**

All grant submissions should describe how the proposed research plans to determine the extent to which the initiatives have met the stated objectives and closed the clinical gap(s).

While not required, it is strongly recommended that the results of these research initiatives aim to increase understanding around the elements identified within the chart within this CGN. Genentech will review ways the aforementioned information ties into the following components:

- Research that results in an improvement of quality metrics, quality of care, and/or quality of life
- Research that results in a way to sustainably improve population health for a community
- Additionally, a plan for publishing the results detailing the lessons learned would be welcomed

**Genentech's Grant Decision-Making Criteria**

Please refer to the publicly available criteria, which can be found at [http://funding.gene.com](http://funding.gene.com).

**Terms and Conditions**

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines.
2. This CGN does not commit Genentech to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reason, and in fairness to all grantees, all communications about this CGN must come exclusively to Genentech’s department for Medical Education & Research Grants. Failure to comply will automatically disqualify grantees.
5. Failure to follow instruction within this CGN may result in a denial.

**Transparency**

Genentech, at its sole discretion, has the right to disclose the details of funded independent research projects, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Genentech website.

**References:**

4. Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue